X Protein of hepatitis B virus potently activates HIV-1 subtype C long terminal repeat promoter: implications for faster spread of HIV-1 subtype C
Gupta, Nidhi; Sood, Vikas; Bano, Aalia S; Banerjea, Akhil C
National Institute of Immunology, JNU Campus, New Delhi 110067, India.
Received 19 January, 2007
Revised 10 March, 2007
Accepted 20 March, 2007
Several genetic subtypes of HIV have been identified throughout the world, but it is predominantly subtype C that is responsible for causing the epidemic in India, some regions of south Asia and Africa. Besides HIV-1 infection, individuals are also co-infected with other pathogens such as hepatitis B virus (HBV), and other bacterial and yeast pathogens. HBV encodes the X gene (HBx) whose product is known to activate several heterologous promoters, including the HIV-1 long terminal repeat (LTR) promoter [1–4]. HIV-1 gene expression is controlled by the LTR promoter, which is rich in various transcription factor binding sites . The HIV-1 LTR sequence of genetic subtype B is significantly different than subtype C, and it is therefore reasonable to assume that HBx may have different effects on promoter activity .
In order to study the possible impact of HBx protein on HIV-1 subtype-specific LTR-mediated activation, we co-transfected HIV-1 LTR-B and C reporter constructs (pBlue-3′-LTR-B and C-Luc) along with HBx encoding DNA, pSG5.HBx (465 nucleotide long X gene is placed under SV40 promoter that allows intracellular expression)  into human 293 cells using lipofectin (Invitrogen, Carlsbad, California, USA) for 48 h. Cell lysates were prepared and the amounts of luciferase were determined according to the manufacturer's instructions (Promega Biotech, Madison, Wisconsin, USA); the results are shown in Fig. 1a (mean of three independent experiments). To ensure uniform transfection efficiency we included an internal reporter control plasmid (pSV-β-gal; Promega). Control cells or cells transfected with 100 ng pSG5.HBx alone showed background luciferase activity. LTR-B and LTR-C reporter plasmids showed basal promoter activity, and the latter showed approximately twofold more basal activity. When co-transfected with 100 ng of either LTR-B or LTR-C plasmids along with 100 ng pSG5.HBx construct, the latter combination (LTR-C plus HBx) showed more than sevenfold more activation when compared with basal activity, whereas it was less than twofold with LTR-B plus HBx combination. When 100 ng of each LTR and 100 ng of pSG5.HBx DNA were used for transfection, the pattern and the extent of activation remained unchanged. When co-transfected with HBx plus B-Tat (cytomegalovirus promoter driven Tat derived from pNL4-3DNA) plus reporter construct (LTR-B-luciferase), a strong synergistic effect was observed. It is noteworthy that the level of LTR-B promoter activation by the HBx protein is equivalent to what we observed with LTR plus B-TAT interaction (mean ± SD from three experiments, Fig. 1b).
This is the first study that suggests that the HBx protein might play an important role in upregulating HIV-1 subtype-C LTR-mediated gene expression compared with subtype-LTR-B-driven expression. These observations have strong implications for the increased replication of subtype C virus.
HIV-1 subtype-B and C-LTR-luciferase vectors and pNL4-3 DNA plasmid DNA were obtained from the AIDS Research and Reference Reagent Program of National Institutes of Health, Bethesda, Maryland, USA. Plasmid pSG5.HBx was a gift from Vijay Kumar, ICGEB, New Delhi, India.
Sponsorship: This work was supported by a grant from the Department of Biotechnology, Government of India to the National Institute of Immunology, New Delhi, and to the corresponding author (A.C.B).
1. Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals. J Biol Chem 2001; 276:35435–35443.
2. Keasler VV, Hodgson AJ, Madden CR, Slagle BL. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol 20 December 2006; E-pub ahead of print.
3. Goila R, Banerjea AC. Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 2001; 353:701–708.
4. Goila R, Banerjea AC. Sequence specific cleavage of hepatitis X RNA in cis and trans- by novel mono- and multitarget hammerhead motif containing ribozymes. Oligonucleotides 2004; 14:249–262.
5. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucl Acids Res 2000; 28:663–668.
6. Kumar V, Jayasuryan N, Kumar R. A truncated mutant (residues 58–140) of the hepatitis B virus X protein retains transactivating function. Proc Natl Acad Sci USA 1996; 93:5647–5652.
© 2007 Lippincott Williams & Wilkins, Inc.